ARID1A has prognostic value in acute myeloid leukemia and promotes cell proliferation via TGF-β1/SMAD3 signaling

• Published in: Clinical and experimental medicine Vol. 23; no. 3; pp. 777 - 785
• Main Authors: Ren, Tianying, Wang, Jing, Tang, Wenqiang, Chen, Dongliang, Wang, Shuang, Zhang, Xiaole, Yang, Dawei
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2023; Springer Nature B.V
• Subjects: Acute myeloid leukemia; Apoptosis; Cell cycle; Cell growth; Cell proliferation; Chromatin remodeling; Hematology; Internal Medicine; Leukemia; Medicine; Medicine & Public Health; Molecular modelling; Oncology; Original Article; Remission; Remission (Medicine); Signal transduction; Smad3 protein; Therapeutic targets; Transforming growth factor-b1; Tumor suppressor genes; Tumorigenesis; AML; Relapse; TGF-β1/ SMAD3; ARID1A; Tumor suppressor
• DOI: 10.1007/s10238-022-00863-8
• ISSN: 1591-9528; 1591-8890

Previous studies have shown that the gene AT-rich interactive domain-containing protein 1A (ARID1A) is a subunit of SWI/SNF chromatin remodeling complex that acts as a tumor suppressor gene in several cancers and plays a vital role in tumorigenesis. However, its biological functions in acute myeloid leukemia (AML) are still unclear. Here, we tried to elaborate the expression of ARID1A in patients with AML, in leukemia cells, as well as the molecular mechanisms. Our results indicated that the expression of ARID1A was significantly downregulated in the bone marrow of patients with AML and relapsed patients compared with healthy subjects and patients in complete remission. Meantime, receiver operating characteristic curve analysis showed that the expression of ARID1A could be used to discriminate between patients with AML and patients in complete remission. We further constructed a knockdown cell model to determine the regulatory mechanisms of ARID1A in AML cells. We found that the decreased expression of ARID1A promoted cell proliferation, suppressed cellular apoptosis, and impeded cell cycle arrest via TGF-β1/SMAD3 signaling pathway. These results revealed that the reduced expression of ARID1A promoted cell proliferation via the TGF-β1/SMAD3 cascade and served as a prognostic biomarker for AML and therapeutic targets.